Autophagy is the process by which cells remove damaged proteins, recycle worn-out organelles (e.g., mitochondria), clear cellular waste and provide nutrients during stress. Autophagy is essential for muscles because they are constantly under mechanical stress. If autophagy is too low, damaged proteins accumulate and muscle gradually weakens. If it is too high, muscle tissue can begin breaking itself down.
Disruption of autophagy has been implicated in a wide range of muscle disorders, and abnormal muscle autophagy is frequently observed in neurogenic diseases. However, the neuronal signaling pathways that control this process had previously remained largely unknown.
Now, researchers led by Prof. Zhang Hong from the Institute of Biophysics of the Chinese Academy of Sciences have identified two parallel neuronal circuits that regulate the autophagy-lysosome pathway in the body wall muscle of Caenorhabditis elegans, a tiny nematode worm. Their research has uncovered a previously unknown mechanism by which the worm’s nervous system maintains muscle homeostasis.
Genomic surveillance—the process of monitoring and sequencing pathogens—is one of the most important tools for detecting emerging viral threats. But global surveillance systems remain costly, unevenly distributed and often are too slow to identify dangerous variants before they spread internationally, amplifying future disease outbreak threats.
A recently published research paper in Nature Communications, co-authored by Dr. Patricia Ning, assistant statistics professor, and Jifan Li, a doctoral candidate in the Department of Statistics, along with collaborators from multiple international institutions, introduces a new framework to address these issues while using fewer resources, making genomic surveillance rapid and cost-effective in preparation for new strains of COVID-19.
Ning’s algorithm works to strengthen local, community-based surveillance capacity in all regions in anticipation of future pandemics.
A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center (DKFZ), Mannheim University Medical Center, Heidelberg University Hospital and numerous partner institutions have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.
Gliomas are usually incurable brain tumors that are difficult to remove completely through surgery. Chemotherapy and radiation therapy are also effective only to a limited extent. These tumors often share a key characteristic: In most cases, the cancer cells carry a common genetic mutation. An identical genetic error causes a specific amino acid to be substituted in the IDH1 enzyme. This results in a novel protein structure—a so-called neoepitope. What makes this special is that the neoepitope drives tumor growth and, at the same time, is recognized as foreign by the patient’s immune system, making it an ideal target for immunotherapies.
The research team from Heidelberg/Mannheim and Tübingen developed a peptide vaccine that specifically trains the immune system to recognize and fight tumor cells with this mutation. The vaccine was tested for safety and efficacy in a phase 1 clinical trial (NOA 16) involving 33 patients with newly diagnosed high-grade astrocytomas, the most common form of glioma. The patients received the vaccine in addition to standard therapy consisting of surgery, radiation therapy and chemotherapy. The work is published in the journal Nature Cancer.
Age-related neurodegenerative disorders, including dementia, are a major global health concern. This article describes the first comprehensive, data-driven molecular model of the neuro-glia-vascular system to explore the complex relationships between the aging brain, energy metabolism, blood flow, and neuronal activity. Comprising 16,800 interaction pathways, the model includes all key enzymes, transporters, metabolites, and circulatory factors vital for neuronal electrical activity. We found significant alterations in metabolite concentrations and differential effects on adenosine triphosphate (ATP) supply in neurons and astrocytes and within subcellular compartments in aged brains and identified reduced sodium/potassium adenosine triphosphatase (Na+/K+-ATPase) activity as the leading cause of impaired neuronal action potentials.
For the past months, I’ve been building DiGem — a project focused on creating a Human Digital Twin: a digital representation of a person that combines health data, AI, lifestyle habits, and gamification into one system.
Imagine:
⚡ Your body displayed as a dashboard 🧠 AI acting as your personal health coach 📈 Real-time monitoring of your health and performance 🎮 Improving yourself through levels, XP, and achievements 🧬 A digital twin that evolves together with you.
On Sunday, July 5, 2026, at 1 p.m. U.S. Pacific Time, watch a compilation stream of four additional presentations from the May 2–3, 2026, sessions at the University of California, Berkeley Conference on Aging and Longevity (BerkeleyCAL), hosted by Professor Steven A. Garan, Director of Bioinformatics at the Center for Research and Education on Aging.
These presentations focus key insights in geroscience, both from its history and in regard to promising future directions and some implications for effective advocacy; they are delivered by some of the leading researchers in longevity science – Aubrey de Grey, Brendan Hughes, Felipe Sierra, and Michael West. Three of the presentations include question-and-answer sessions.
Dr. Aubrey de Grey of the Longevity Escape Velocity Foundation (LEVF) discusses the historical approaches to viewing aging and their shortcomings, as well as the damage-repair approach that he has championed and its prospects for rejuvenating the body. He also discusses implications for advocacy and which tactics could be more effective in bringing the public on board. Note: This presentation is an excerpt, captured by USTP Chairman Stolyarov on his phone camera. It is being made available due to the official recording having been lost.
Dr. Brendan Hughes from the Buck Institute discusses his thesis research on how DNA damage shapes unique, disease-relevant senescent cell states in neurons and other brain cell types. He details a methodology involving the direct differentiation of fibroblasts into neurons and oligodendrocytes to better understand aging-related cellular responses and potential therapeutic targets for Alzheimer’s disease. Dr. Hughes also highlights the importance of basic research in developing future interventions, such as senescence-targeted therapies or DNA repair modulations. The question-and-answer session includes a question from USTP Chairman Stolyarov to Dr. Hughes.
Dr. Felipe Sierra advocates for a shift in geroscience from solely targeting age-related diseases to focusing on maintaining intrinsic health and functional capacity. He proposes that molecular resilience acts as the crucial link between aging biology and long-term health, suggesting that strengthening this resilience could prevent the onset of multiple morbidities. Ultimately, he calls for more robust longitudinal studies and clinical trials that prioritize health-span metrics over the traditional, disease-centered approach to geriatric medicine.
Dr. Michael West explores the biological dichotomy between mortal somatic cells and the immortal germline to explain the fundamental mechanisms of aging and cellular regeneration. He discusses the history of stem-cell research and his work on telomeres and nuclear transfer, which demonstrated that developmental aging and cellular differentiation are reversible processes. Dr. West proposes a new approach to regenerative medicine that focuses on unlocking the body’s innate potential by targeting heterochrony genes to combat chronic degenerative diseases.
Treatment of induced pluripotent stem cells with Norrin and vitronectin, and subsequent cell sorting and maturation, generates retinal-like endothelial cells that can regenerate retinal vasculature in an oxygen-induced retinopathy mouse and recapitulate enhanced inner blood–retinal barrier properties when co-cultured with retinal-like pericytes.
